SEC Form 4 · accession 0001140361-17-010973

NEVRO CORP · NVRO

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — VP of Sales

Period of report

Mar 6, 2017

Accepted (ET)

Mar 8, 2017 · 11:51 am EST

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001444380

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I
Common Stock^F2	Mar 6, 2017	S	37,000	$90.989	D	40,463	D
Common Stock^F2	Mar 6, 2017	M	1,500	$3.60	A	41,963	D
Common Stock^F3,F2	Mar 6, 2017	S	800	$90.9038	D	41,163	D
Common Stock^F4,F2	Mar 6, 2017	S	600	$92.3533	D	40,563	D
Common Stock^F2	Mar 6, 2017	S	100	$92.85	D	40,463	D

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Stock Option (Right to Buy)^F5	$3.60	Mar 6, 2017	M	1,500	D	—	Dec 17, 2022	Common Stock	1,500	38,608	D

F1The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan.
F2Includes 2,500 restricted stock units.
F3The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $90.80 to $91.13, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
F4The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $91.81 to $92.71, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
F5100% of the shares subject to the option are fully vested and exercisable.